News

Labor is taking comments on the plan until April 28.

The hospital alleges $1.4 million in withheld post-bankruptcy payments following an earlier $250 million reimbursement lawsuit.

The price drop builds on concerted efforts by Novo Nordisk to improve patient access, particularly to weight-loss drugs Wegovy and Ozempic, according to company officials.

The initial focus is on GLP-1 medications, a category that has seen significant demand but variable insurance coverage.

The plaintiffs say the HHS secretary's assurances that coverage will continue are "open to suspicion."

Access Health CT officials expect to offer the cash-for-coverage plans alongside traditional small-group plans.